Mohit Bansal
Stock Analyst
(n/a)
# 4,647
Out of 4,654 analysts
140
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Equal-Weight | $125 → $110 | $101.88 | +7.97% | 10 | Nov 1, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,200 → $1,050 | $843.60 | +24.47% | 15 | Oct 22, 2024 | |
| TVTX Travere Therapeutics | Upgrades: Overweight | $9 → $27 | $17.57 | +53.67% | 4 | Oct 21, 2024 | |
| HALO Halozyme Therapeutics | Downgrades: Equal-Weight | $58 → $62 | $57.15 | +8.49% | 5 | Oct 7, 2024 | |
| GILD Gilead Sciences | Upgrades: Overweight | $78 → $100 | $89.51 | +11.72% | 8 | Oct 7, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $115 → $90 | $66.60 | +35.14% | 5 | Sep 17, 2024 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Overweight | $14 → $12 | $4.19 | +186.40% | 3 | Aug 9, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $875 → $1,000 | $818.93 | +22.11% | 15 | Aug 9, 2024 | |
| AMGN Amgen | Downgrades: Equal-Weight | $320 → $335 | $319.22 | +4.94% | 8 | Aug 7, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $240 → $225 | $173.79 | +29.47% | 11 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $120 | $110.45 | +8.65% | 1 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $28.09 | +6.80% | 9 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $205 | $203.55 | +0.71% | 6 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $540 → $555 | $471.12 | +17.80% | 8 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $122.21 | +39.10% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $52 | $54.32 | -4.27% | 7 | Apr 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $13.45 | +100.74% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $41.69 | +19.93% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $4.18 | +44,756.46% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $16.40 | +82.93% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.25 | +2,780.00% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $22.31 | -14.84% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.80 | +525.16% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $2.98 | +1,913.42% | 4 | Dec 3, 2019 |
Merck & Co.
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $101.88
Upside: +7.97%
Regeneron Pharmaceuticals
Oct 22, 2024
Maintains: Overweight
Price Target: $1,200 → $1,050
Current: $843.60
Upside: +24.47%
Travere Therapeutics
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $17.57
Upside: +53.67%
Halozyme Therapeutics
Oct 7, 2024
Downgrades: Equal-Weight
Price Target: $58 → $62
Current: $57.15
Upside: +8.49%
Gilead Sciences
Oct 7, 2024
Upgrades: Overweight
Price Target: $78 → $100
Current: $89.51
Upside: +11.72%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $66.60
Upside: +35.14%
Ironwood Pharmaceuticals
Aug 9, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $4.19
Upside: +186.40%
Eli Lilly
Aug 9, 2024
Maintains: Overweight
Price Target: $875 → $1,000
Current: $818.93
Upside: +22.11%
Amgen
Aug 7, 2024
Downgrades: Equal-Weight
Price Target: $320 → $335
Current: $319.22
Upside: +4.94%
Biogen
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $240 → $225
Current: $173.79
Upside: +29.47%
Aug 1, 2024
Maintains: Equal-Weight
Price Target: $140 → $120
Current: $110.45
Upside: +8.65%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $28.09
Upside: +6.80%
Jul 26, 2024
Maintains: Overweight
Price Target: $200 → $205
Current: $203.55
Upside: +0.71%
Jun 24, 2024
Maintains: Overweight
Price Target: $540 → $555
Current: $471.12
Upside: +17.80%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $122.21
Upside: +39.10%
Apr 18, 2024
Maintains: Equal-Weight
Price Target: $51 → $52
Current: $54.32
Upside: -4.27%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $13.45
Upside: +100.74%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $41.69
Upside: +19.93%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $4.18
Upside: +44,756.46%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $16.40
Upside: +82.93%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.25
Upside: +2,780.00%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $22.31
Upside: -14.84%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.80
Upside: +525.16%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $2.98
Upside: +1,913.42%